Exagen Inc. (NASDAQ:XGN) Short Interest Up 32.7% in February

Exagen Inc. (NASDAQ:XGN – Get Rating) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 21,500 shares, an increase of 32.7% from the February 13th total of 16,200 shares. Based on an average trading volume of 28,500 shares, the short-interest ratio is currently 0.8 days. Currently, 0.2% of the shares of the stock are sold short.

Exagen Stock Up 0.4 %

NASDAQ XGN opened at $2.43 on Friday. Exagen has a 1-year low of $2.10 and a 1-year high of $9.44. The company has a market cap of $39.51 million, a price-to-earnings ratio of -1.07 and a beta of 1.26. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $2.67 and a 200-day moving average of $2.91.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Canaccord Genuity Group reduced their price target on Exagen from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 15th. Canaccord Genuity Group dropped their price objective on Exagen from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 15th. Cowen dropped their price objective on Exagen to $7.00 in a research note on Thursday, November 17th. Finally, BTIG Research dropped their price objective on Exagen from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 17th.

Institutional Trading of Exagen

A number of institutional investors have recently bought and sold shares of XGN. Advisors Capital Management LLC raised its holdings in shares of Exagen by 66.2% in the 3rd quarter. Advisors Capital Management LLC now owns 67,923 shares of the company’s stock worth $143,000 after acquiring an additional 27,050 shares during the last quarter. RTW Investments LP boosted its holdings in Exagen by 2.3% in the 3rd quarter. RTW Investments LP now owns 1,048,662 shares of the company’s stock worth $2,842,000 after buying an additional 23,660 shares during the period. Stonepine Capital Management LLC boosted its holdings in Exagen by 0.4% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,265,373 shares of the company’s stock worth $3,429,000 after buying an additional 4,986 shares during the period. UBS Group AG boosted its holdings in Exagen by 3.9% in the 3rd quarter. UBS Group AG now owns 136,813 shares of the company’s stock worth $370,000 after buying an additional 5,144 shares during the period. Finally, Brinker Capital Investments LLC boosted its holdings in Exagen by 9.4% in the 3rd quarter. Brinker Capital Investments LLC now owns 99,115 shares of the company’s stock valued at $269,000 after purchasing an additional 8,519 shares during the period. Institutional investors own 53.90% of the company’s stock.

About Exagen

(Get Rating)

Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).